Aditum Bio and Leads Biolabs Form Oblenio Bio to Develop Tri-Specific T-Cell Engager for Autoimmune Disorders
Aditum Bio and Leads Biolabs Form Oblenio Bio to Develop Tri-Specific T-Cell Engager for Autoimmune Disorders
11/07/24, 8:21 AM
Money
$614 million
Industry
biotechnology
Type
partnership
Aditum Bio and Leads Biolabs have formed a partnership to create Oblenio Bio, with an exclusive option and license agreement to develop LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cell engager antibody for autoimmune diseases. The collaboration aims to rapidly bring LBL-051 into clinical studies to address unmet needs for increased efficacy and durability in difficult-to-treat autoimmune diseases.